Merck acquires mRNA contract manufacturing firm AmpTec

Merck acquires mRNA contract manufacturing firm AmpTec

11:07 AM, 12th January 2021
Merck-AmpTec-acquisition
Merck acquires AmpTec, a Hamburg, Germany-based, mRNA contract development and manufacturing organization, to expand its capabilities for customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases.

DARMSTADT, GERMANY: Merck announced it will acquire AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.

“The success of mRNA-based vaccines for Covid-19 lays the path to accelerate the development of these therapeutics for many other diseases,” said Stefan Oschmann, chairman, executive board and CEO of Merck. “By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market. This transaction is another important step to support the constant growth of our Life Science business through tailored, small-scale acquisitions with high impact.”

“Last year, AmpTec celebrated its fifteenth anniversary, and this acquisition marks an exciting new chapter for our company,” said Guido Krupp and Peter Scheinert, managing directors and founders of AmpTec. “AmpTec’s more than 40 employees are thrilled to join Merck and are confident that our PCR-based technology and combined expertise will allow us to offer customers innovative technologies, products and services to help advance life-enhancing therapeutics.”

Lipids, which are part of the SAFC® portfolio in Merck’s Life Science business sector, constitute one of the critical components for the formulation of mRNA therapeutics including Covid-19 vaccines. Merck, with more than 20 years’ experience in this space, is collaborating with more than 50 vaccine manufacturers – some of which use mRNA for their products – to support their efforts in the development and production of Covid-19 vaccines, treatments and services.

PCR technology is another important component of mRNA manufacturing. AmpTec uses a differentiated PCR-based technology for mRNA manufacturing, which has shown to have advantages over other manufacturing technologies, including:
•    Advantages in homogeneity, purity, activity and flexibility.
•    Higher quality and improved performance.
•    Flexible capping options to reach specific performance requirements.

In addition to specializing in mRNA technology, AmpTec has a diagnostics business that focuses on producing customized long RNAs and DNAs for in vitro diagnostics. It will complement Merck’s diagnostics business, which specializes in providing critical raw materials, components and services for in vitro diagnostics manufacturers. Merck’s molecular materials portfolio includes custom and predesigned DNA oligos and probes for a variety of applications such as PCR, next generation sequencing and microarray production.

Merck is continuing to invest in mRNA as a modality and will scale up this technology both at AmpTec’s existing site in Hamburg and at Merck’s global headquarters in Darmstadt, Germany.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Enhanced oil recovery is key driver for oilfield surfactants consumption

The global oilfield surfactants industry is set to witness some remarkable developments over the next few years, with increasing number of oil & g ...

Read more
Three major trends fostering water softener market growth

The water softener market is poised to amass noteworthy gains in the coming years owing to supportive regulatory amendments by EU concerning clean wat ...

Read more
Chromate-free pretreatment coatings, a vital trend to boost sustainability in aerospace

Development of a holistic solution for corrosion-related issues has led to technological advancements in pretreatment coatings. When it comes to boost ...

Read more
Industrial floor coatings to see traction across manufacturing, warehousing sectors

A key vertical within the polymers and advanced materials space, the global industrial floor coatings industry has witnessed some interesting trends i ...

Read more
Underlining demand for antimicrobial coatings in healthcare facilities

With cleanliness and hygiene now becoming a top-notch priority—thanks to COVID-19—uniqueness and relevance of antimicrobial coatings have ...

Read more
Total acquires Fonroche Biogaz, becomes renewable gas leader in France

PARIS, FRANCE: Total announces the acquisition of Fonroche Biogaz, a company that designs, builds and operates anaerobic digestion units in France. Wi ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X